注射ドラッグデリバリー市場：デバイスタイプ、使用性、治療用途、エンドユーザー別-2025-2030年世界予測

注射ドラッグデリバリー市場は、2023年に9,722億5,000万米ドルと評価され、2024年には1兆420億6,000万米ドルに達すると予測され、CAGR 7.58％で成長し、2030年には1兆6,217億1,000万米ドルに達すると予測されています。

注射ドラッグデリバリーとは、注射によって体内に薬剤を投与することを指し、経口やその他の非侵襲的な経路では効果的に代謝されない薬剤を送達するための重要な手段を提供します。注射ドラッグデリバリーの必要性は、治療作用の迅速な発現、投与量の正確さ、慢性疾患の管理、予防接種、緊急事態に不可欠であることに起因します。主な用途は、がん、糖尿病、心血管疾患、ワクチンなど多岐にわたり、最終用途はヘルスケア施設、在宅ケア環境、専門クリニックなど多岐にわたる。この市場の成長は、生物製剤の進歩、慢性疾患の有病率の増加、スマートデバイスや自己注射デバイスなどの技術革新によって推進されます。さらに、生物製剤やバイオシミラーの台頭により、新規かつ効果的な注射送達システムに対する需要が高まっています。

しかし、開発コストの高さ、規制の枠組みの厳しさ、患者のコンプライアンスをめぐる問題、針を使用するシステムに関連する安全性リスクなど、大きな課題が残っています。機会は、アドヒアランスと患者管理を改善する、針を使わない技術やIoTを活用したコネクテッドデバイスの開発にあります。市場拡大には、プレフィルドシリンジや自動注射器の普及、ウェアラブル注射器の進歩、デジタルヘルス技術の統合などが影響するとみられます。こうした機会を活用するために、企業は患者中心の設計のための研究開発に投資し、ドラッグデリバリーの体験を高めるためにテクノロジー企業と協力すべきです。また産業界は、製造の複雑さやバイオアベイラビリティの問題など、成長を阻害する可能性のある制約の克服にも注力すべきです。さらに、革新的な分野としては、マイクロニードルパッチ、生分解性ポリマー、徐放性デリバリーシステムなどの開発があり、従来のパラダイムを破壊することが期待されます。この市場の特徴は、個別化医療へのシフトが進むというダイナミックな性質にあり、競争力を維持するためには規制状況や技術状況を常に監視する必要があります。

市場力学：急速に進化する注射ドラッグデリバリー市場の主要市場インサイトを公開

注射ドラッグデリバリー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 針技術の技術的進歩
  • 慢性疾患の増加
  • 世界の高齢者人口の大幅な増加
• 市場抑制要因
  • 注射ドラッグデリバリーソリューションの開発コストの高さ
• 市場機会
  • スマート注射デバイスの開発
  • 自己投与デバイスの需要増加
• 市場の課題
  • 注射針に対する患者のコンプライアンスの低さ、注射器具の使用に関するトレーニング不足

ポーターのファイブフォース：注射ドラッグデリバリー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：注射ドラッグデリバリー市場における外部からの影響の把握

外部マクロ環境要因は、注射ドラッグデリバリー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析注射ドラッグデリバリー市場における競合情勢の把握

注射ドラッグデリバリー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス注射ドラッグデリバリー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、注射ドラッグデリバリー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨注射ドラッグデリバリー市場における成功への道筋を描く

注射ドラッグデリバリー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 針技術の技術的進歩
    • 慢性疾患の増加
    • 世界中で高齢者人口が急増
  • 抑制要因
    • 注射ドラッグデリバリーソリューションの開発コストが高い
  • 機会
    • スマート注射装置の開発
    • 自己投与デバイスの需要増加
  • 課題
    • 患者の注射針コンプライアンスが低く、注射器具の使用に関するトレーニングが不足している
• 市場セグメンテーション分析
  • デバイスの種類：使いやすさから自己注射デバイスが好まれる傾向が高まっている
  • エンドユーザー：安全性と携帯性を考慮し、在宅ケアの現場での応用を検討
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 注射ドラッグデリバリー市場デバイスタイプ別

• 従来の注射装置
• 自己注射器
  • オートインジェクター
  • 無針注射器
  • ペン型注射器
  • ウェアラブルインジェクター

第7章 注射ドラッグデリバリー市場：ユーザビリティ別

• 使い捨て
• 再利用可能

第8章 注射ドラッグデリバリー市場治療用途別

• 自己免疫疾患
• がん
• 慢性疾患
• ホルモン療法
• 感染症

第9章 注射ドラッグデリバリー市場：エンドユーザー別

• ホームケア設定
• 病院・クリニック

第10章 南北アメリカの注射ドラッグデリバリー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の注射ドラッグデリバリー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの注射ドラッグデリバリー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ステヴァナートグループ、患者ケアと持続可能性の向上を目的とした革新的な体内ドラッグデリバリーシステム「Vertiva」を発表
  • Altavizが、ドラッグデリバリー効率を高める革新的な自動注射器プラットフォームAltaVISCを発表
  • UDENYCA自動注射器の発売により患者のアクセス性と投与効率が向上
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Antares Pharma by Halozyme Therapeutics
• Becton, Dickinson and Company
• Eli Lilly and Company
• Emperra GmbH
• Enable Injections LLC
• F. Hoffman-La Roche Ltd.
• Insulet Corporation
• Johnson & Johnson Services, Inc.
• Medtronic PlC
• Novo Nordisk A/S
• Pfizer, Inc.
• Ravimed Sp. z o.o.
• Recipharm AB
• Sanofi S.A.
• SiO2 Medical Products
• Stevanato Group
• Tandem Diabetes Care
• West Pharmaceutical Services, Inc.
• Wilhelm Haselmeier GmbH & Co. KG

LIST OF FIGURES

• FIGURE 1. INJECTABLE DRUG DELIVERY MARKET RESEARCH PROCESS
• FIGURE 2. INJECTABLE DRUG DELIVERY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INJECTABLE DRUG DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INJECTABLE DRUG DELIVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INJECTABLE DRUG DELIVERY MARKET DYNAMICS
• TABLE 7. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY CONVENTIONAL INJECTION DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY REUSABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 45. CANADA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 46. CANADA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 72. CHINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 73. CHINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 77. INDIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 78. INDIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 163. ITALY INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 164. ITALY INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 183. POLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 184. POLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 188. QATAR INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 189. QATAR INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET SIZE, BY SELF-INJECTION DEVICES, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET SIZE, BY USABILITY, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. INJECTABLE DRUG DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

The Injectable Drug Delivery Market was valued at USD 972.25 billion in 2023, expected to reach USD 1,042.06 billion in 2024, and is projected to grow at a CAGR of 7.58%, to USD 1,621.71 billion by 2030.

Injectable drug delivery refers to the administration of medications into the body through injections, offering a critical avenue for delivering drugs that cannot be effectively metabolized through oral or other non-invasive routes. The necessity for injectable drug delivery stems from its ability to provide rapid onset of therapeutic action, precision in dosage administration, and is vital for managing chronic diseases, vaccinations, and emergency situations. Key applications span a wide range including oncology, diabetes, cardiovascular diseases, and vaccines, with end-use diverging across healthcare facilities, homecare settings, and specialized clinics. Growth in this market is propelled by advancements in biologics, increasing prevalence of chronic diseases, and technological innovations such as smart and self-injecting devices. Additionally, the rise of biologics and biosimilars is increasing demand for novel and effective injectable delivery systems.

However, substantial challenges persist, including the high cost of development, stringent regulatory frameworks, and issues around patient compliance and safety risks associated with needle-based systems. Opportunities lie in the development of needle-free technologies and connected devices powered by IoT that improve adherence and patient management. Market expansion is likely influenced by the increasing popularity of pre-filled syringes and auto-injectors, advancements in wearable injectors, and the integration of digital health technologies. To capitalize on these opportunities, companies should invest in R&D for patient-centric designs and collaborate with technology firms to enhance the drug delivery experience. Industries should also focus on overcoming limitations such as manufacturing complexities and bioavailability issues that may impede growth. Furthermore, innovation areas include the development of microneedle patches, biodegradable polymers, and sustained-release delivery systems that promise to disrupt traditional paradigms. The market is characterized by its dynamic nature, with an increasing shift towards personalized medicine, which mandates constant surveillance of regulatory and technological landscapes to remain competitive.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Injectable Drug Delivery Market

The Injectable Drug Delivery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Technological advancements in needle technology
  • Increasing prevalence of chronic diseases
  • Significant rise in elderly population worldwide
• Market Restraints
  • High development costs of injectable drug delivery solutions
• Market Opportunities
  • Development of smart injection devices
  • Increasing demand for self-administration devices
• Market Challenges
  • Low patient compliance of needles and lack of training in using injectable devices

Porter's Five Forces: A Strategic Tool for Navigating the Injectable Drug Delivery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Injectable Drug Delivery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Injectable Drug Delivery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Injectable Drug Delivery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Injectable Drug Delivery Market

A detailed market share analysis in the Injectable Drug Delivery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Injectable Drug Delivery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Injectable Drug Delivery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Injectable Drug Delivery Market

A strategic analysis of the Injectable Drug Delivery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drug Delivery Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma by Halozyme Therapeutics, Becton, Dickinson and Company, Eli Lilly and Company, Emperra GmbH, Enable Injections LLC, F. Hoffman - La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PlC, Novo Nordisk A/S, Pfizer, Inc., Ravimed Sp. z o.o., Recipharm AB, Sanofi S.A., SiO2 Medical Products, Stevanato Group, Tandem Diabetes Care, West Pharmaceutical Services, Inc., and Wilhelm Haselmeier GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Injectable Drug Delivery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Device Type, market is studied across Conventional Injection Devices and Self-injection Devices. The Self-injection Devices is further studied across Autoinjectors, Needle-free Injectors, Pen Injectors, and Wearable Injectors.
• Based on Usability, market is studied across Disposable and Reusable.
• Based on Therapeutic Application, market is studied across Autoimmune Diseases, Cancer, Chronic Diseases, Hormonal Therapies, and Infectious Diseases.
• Based on End-user, market is studied across Home Care Settings and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Technological advancements in needle technology
    • 5.1.1.2. Increasing prevalence of chronic diseases
    • 5.1.1.3. Significant rise in elderly population worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High development costs of injectable drug delivery solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of smart injection devices
    • 5.1.3.2. Increasing demand for self-administration devices
  • 5.1.4. Challenges
    • 5.1.4.1. Low patient compliance of needles and lack of training in using injectable devices
• 5.2. Market Segmentation Analysis
  • 5.2.1. Device Type: Increasing preference for self-injection devices due to ease of use
  • 5.2.2. End-user: Exploring applications in home care settings due to safety and portability
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Injectable Drug Delivery Market, by Device Type

• 6.1. Introduction
• 6.2. Conventional Injection Devices
• 6.3. Self-injection Devices
  • 6.3.1. Autoinjectors
  • 6.3.2. Needle-free Injectors
  • 6.3.3. Pen Injectors
  • 6.3.4. Wearable Injectors

7. Injectable Drug Delivery Market, by Usability

• 7.1. Introduction
• 7.2. Disposable
• 7.3. Reusable

8. Injectable Drug Delivery Market, by Therapeutic Application

• 8.1. Introduction
• 8.2. Autoimmune Diseases
• 8.3. Cancer
• 8.4. Chronic Diseases
• 8.5. Hormonal Therapies
• 8.6. Infectious Diseases

9. Injectable Drug Delivery Market, by End-user

• 9.1. Introduction
• 9.2. Home Care Settings
• 9.3. Hospitals & Clinics

10. Americas Injectable Drug Delivery Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Injectable Drug Delivery Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drug Delivery Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Stevanato Group Launches Vertiva, An Innovative On-Body Drug Delivery System for Enhanced Patient Care and Sustainability
  • 13.3.2. Altaviz Introduces AltaVISC, A Revolutionary Auto-injector Platform Enhancing Drug Delivery Efficiency
  • 13.3.3. Launch of UDENYCA Autoinjector Enhances Patient Accessibility and Administration Efficiency
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Antares Pharma by Halozyme Therapeutics
• 3. Becton, Dickinson and Company
• 4. Eli Lilly and Company
• 5. Emperra GmbH
• 6. Enable Injections LLC
• 7. F. Hoffman - La Roche Ltd.
• 8. Insulet Corporation
• 9. Johnson & Johnson Services, Inc.
• 10. Medtronic PlC
• 11. Novo Nordisk A/S
• 12. Pfizer, Inc.
• 13. Ravimed Sp. z o.o.
• 14. Recipharm AB
• 15. Sanofi S.A.
• 16. SiO2 Medical Products
• 17. Stevanato Group
• 18. Tandem Diabetes Care
• 19. West Pharmaceutical Services, Inc.
• 20. Wilhelm Haselmeier GmbH & Co. KG